Whether you’re celebrating a funding round, research collaboration, FDA-approval, or commemorating a deal in the biotech space, you’ll find inspiration in the custom designs below.

Clear acrylic deal toy featuring a vial inside, with text and logo for Maverick Therapeutics, commemorating the initiation of the EGFR x CD3 COBRA Phase 1/2 study in February 2021.

DNA Strand-Inspired Merger Deal Toy

Crystal deal toy, incorporating a 3D etching of a DNA strand, commemorating the merger of biotech companies Atrin Pharmaceuticals and Aprea Therapeutics. (22ALJ234)

1 Image

South Carolina-Themed Financial Tombstone

Crystal financial tombstone recognizing the acquisition of Pathology Consultants. The life sciences company is based in Greenville, South Carolina. (23AZH099)

1 Image

Direct Offering Lucite Deal Tombstone

Lucite deal tombstone marking a registered direct offering of stock by AlloVir. The clinical-stage cell therapy firm is based in Waltham, Massachusetts. (22AZH231)

2 Images
Side view of financial tombstone recognizing a registered direct offering of common stock.

Gene Therapy Lucite Tombstone

Lucite tombstone recognizing the acquisition of GeneTx BioTherapeutics. GeneTx has focused on a therapy for Angelman syndrome, a rare neurogenic disease. (22ALJ280)

2 Images
Custom Lucite marking the acquisition of GeneTx, an Illinois-based developer of treatments for rare genetic disorders.

Live-Cell Imaging Deal Toy

Lucite deal toy commemorating the acquisition of CytoSMART, a Dutch firm specializing in live-cell imaging analysis. The acquirer, Axion BioSystems, is an Atlanta-based life sciences company. (22AZH106)

1 Image

Biopharma Stock Offering Tombstone

Custom financial tombstone recognizing a direct offering of common stock by Salarius Pharmaceuticals. The Houston-based firm develops cancer therapies. (22AJH070)

3 Images
Side view of crystal financial tombstone celebrating a direct offering of stock by Salarius Pharmaceuticals. (22AJH070) Back view of DNA strand-inspired financial tombstone marking an offering by clinical-stage firm Salarius Pharmaceuticals. (22AJH070)

Advanced Testing Laboratory Deal Toy

Lucite deal toy recognizing the acquisition of Cincinnati-based Advanced Testing Laboratory. ATL provides research and development services in such areas as life science, product safety, and analytical chemistry. (22AJH077)

1 Image

Pharmaceutical License Agreement Deal Toy

Lucite deal toy celebrating a license option agreement between Ironwood Pharmaceuticals and COUR, a biotech firm. The agreement centers on COUR’s therapy for PBC, a rare autoimmune disease affecting the liver.

(22ALJ081)
2 Images
Lucite deal toy recognizing a joint venture between Ironwood Pharmaceuticals and biotechnology firm COUR. The collaboration will allow Ironwood to develop and commercialize COUR's liver disease therapy CNP-104.

Radiopharm IPO Deal Toy

Crystal deal toy celebrating the initial public offering on the Australian Securities Exchange (ASX) of Radiopharm Theranostics. The Sydney-based company develops radiopharmaceutical drugs and treatments for cancer.

(21ALJ553)
2 Images
Crystal deal toy marking the ASX debut of Sydney-based biotech Radiopharm Theranostics.

Biotech Deal Toys

Beginning on this page, you’ll find galleries with over 90 images of financial tombstones and deal toys from the biotech and life sciences space. You’ll find a number of custom designs playing off visual elements commonly associated with this space, including DNA strands, pills, lab beakers, periodic tables, as well as ones incorporating actual drug vials.

As you might also expect, you’ll see a number of deal toys involving internationally recognized firms and players. These include Takeda Pharmaceutical, Horizon Therapeutics, Gilead Sciences, Roche, Neurocrine, and Bayer. You’ll see as well tombstones commemorating transactions common to this sector involving these and other firms: joint ventures, licensing deals, and development and commercialization agreements.

But you’ll also notice a number of deals commemorated here that may involve far less familiar firms. These include the acquisition of a Dutch company focused on live-cell imaging analytics, and one of an Illinois-based gene therapy firm devoted to the treatment of a rare genetic disorder; the initial public offering of an Australian developer of radiopharmaceutical cancer therapies, and the IPO of a Norwegian biotech making use of marine compounds such as herring roe extract; early-stage funding for a Philadelphia gene engineering startup, and the IPO of an Israeli firm focused on medical applications for lipid-based compounds.

You’ll also notice in these galleries designs not related to any financial transaction. These celebrate a range of awards and employee recognition pieces honoring successful clinical trials, Food and Drug Administration (FDA) and New Drug Application (NDA) submissions, research collaborations and partnerships, and product development milestones.

Contact Us For a Quote Today

"*" indicates required fields

Fill out our quote request form and an associate will be in contact with you as soon as possible.

 

Drop files here or
Accepted file types: tiff, gif, jpg, png, pdf, jpeg, Max. file size: 30 MB, Max. files: 6.
    This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.